Risk factors and outcomes for carbapenem-resistant klebsiella pneumoniae in hematological patients

Abstract

Background Prolonged hospitalization, prolonged neutropenia, and immunosuppressive treatments increase bloodstream infections in hematological patients. Identifying risk factors for carbapenem-resistant Klebsiella pneumonia (CRKP) infection will shed light on controlling the spread of CRKP. Our retrospective study aimed to determine the clinical features, antimicrobial susceptibility, and mortality risk factors of patients who developed CRKP in patients followed up for hematological cancer in the Izmir University of Economics Haematology Department. Material and Methods 19,170 blood-urine-sputum cultures were delivered from the patients, 1,595 (8.31%) of which presented growth. CRKP comprised 302 (1.57%) of such growth cases. The study included 72 patients with hematological malignancy who presented CRKP growth in 302 cultures obtained during the neutropenic fever period. Results The mean age of patients was 51 (18-75 years). Acute myeloid leukemia was the most common disease (n: 26, 36.11%). As to the antibiotic sensitivity of CRKP, 44 patients (61.1%) were colistin sensitive, 28 patients (38.9%) were colistin-resistant, 47 patients (65.3%) were tigecycline sensitive/medium sensitivity, 25 patients (34.7%) were tigecycline resistant, there was no statistically significant difference between antibiotic sensitivities and survival. Conclusions Today, early detection of CRKP colonization in high-risk hematological patients, taking rectal culture, and if the patient presents rectal colonization of CRKP or had CRKP bacteremia during prior hospitalizations, early initiation of treatment with antibiotics acting against CRKP during NPF would significantly reduce mortality.

Keywords

• Carbapenem resistance, klebsiella pneumoniae,
• immunocompromised patient
• infection

References

1. Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014 Apr;27(2):200-10. doi: 10.1097/QCO.0000000000000038.
2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004 Jan 15;100(2):228-37. doi: 10.1002/cncr.11882.
3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.
4. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013 Dec;98(12):1826-35. doi: 10.3324/haematol.2013.091025.
5. Pereira GH, Garcia DO, Mostardeiro M, Fanti KS, Levin AS. Outbreak of carbapenem-resistant Klebsiella pneumoniae: two-year epidemiologic follow-up in a tertiary hospital. Mem Inst Oswaldo Cruz. 2013 Feb;108(1):113-5. doi: 10.1590/s0074-02762013000100019.
6. World Health Organization. Regional Office for Europe. (‎2018)‎. Central Asian and Eastern European Surveillance of Antimicrobial Resistance: Annual report 2018. World Health Organization. Regional Office for Europe. Available at: https://apps.who.int/iris/handle/10665/324806. Accessed August 30, 2022.
7. Maltezou HC. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents. 2009 May;33(5):405.e1-7. doi: 10.1016/j.ijantimicag.2008.09.003.
8. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014 May;58(9):1274-83. doi: 10.1093/cid/ciu052.

9. Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, Chen L, Kreiswirth BN, Walsh TJ, Seo SK. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016 Oct;73(4):336-45. doi: 10.1016/j.jinf.2016.07.002.
10. Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Perriello V, Busca A, Aversa F, Fanci R, Melillo L, Lessi F, Del Principe MI, Cattaneo C, Tumbarello M; HaematologicMalignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne (SEIFEM) group, Italy. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016 Nov;91(11):1076-81. doi: 10.1002/ajh.24489.
11. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013 Sep;13(9):785-96. doi: 10.1016/S1473-3099(13)70190-7.
12. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011 Apr;69(4):357-62. doi: 10.1016/j.diagmicrobio.2010.10.013.
13. Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat. 2010 Aug-Oct;13(4-5):132-8. doi: 10.1016/j.drup.2010.05.002.
14. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016 Feb;16(2):161-8. doi: 10.1016/S1473-3099(15)00424-7.
15. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 Mar 15;34(6):730-51. doi: 10.1086/339215.
16. Febril Nötropeni Çalışma Grubu. Febril nötropenik hastalarda tanı ve tedavi kılavuzu. Flora 2004;9(1):5-28 (in Turkish). Available at: http://www.floradergisi.org/managete/fu_folder/2004-01/2004-9-1-005-028.pdf. Accessed August 30, 2022.
17. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement. CLSI document M100-S25. 2015 Jan;15(3):1-236. Available at: https://file.qums.ac.ir/repository/mmrc/CLSI2015.pdf. Accessed August 30, 2022.
18. Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, Lucet JC, Moro ML, Tacconelli E, Simonsen GS, Szilágyi E, Voss A, Weber JT. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control. 2017 Nov 15;6:113. doi: 10.1186/s13756-017-0259-z.
19. Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017 Oct;39:106-12. doi: 10.1016/j.mib.2017.10.028.
20. Righi E, Peri AM, Harris PN, Wailan AM, Liborio M, Lane SW, Paterson DL. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017 Mar 1;72(3):668-77. doi: 10.1093/jac/dkw459.
21. Kara Ö, Zarakolu P, Aşçioğlu S, Etgül S, Uz B, Büyükaşik Y, Akova M. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond). 2015;47(10):686-93. doi: 10.3109/23744235.2015.1051105.
22. Marimuthu K, Venkatachalam I, Khong WX, Koh TH, Cherng BPZ, Van La M, De PP, Krishnan PU, Tan TY, Choon RFK, Pada SK, Lam CW, Ooi ST, Deepak RN, Smitasin N, Tan EL, Lee JJ, Kurup A, Young B, Sim NTW, Thoon KC, Fisher D, Ling ML, Peng BAS, Teo YY, Hsu LY, Lin RTP, Ong RT, Teo J, Ng OT; Carbapenemase-Producing Enterobacteriaceae in Singapore (CaPES) Study Group. Clinical and molecular epidemiology of carbapenem-resistant enterobacteriaceae among adult inpatients in Singapore. Clin Infect Dis. 2017 May 15;64(suppl_2):S68-S75. doi: 10.1093/cid/cix113.
23. Kahraman S, Ece G, Ocakçı S, Çağırgan S. Hastanemize başvuran hematolojik maligniteli hastalarda allogeneik hematopoetik kök hücre nakli esnasında gelişen enfeksiyonların değerlendirilmesi (in Turkish). Oral presented at: XXXVIII Türk Mikrobiyoloji Kongresi; 4-8 Kasım 2018; Antalya, Turkey.
24. Jaiswal SR, Gupta S, Kumar RS, Sherawat A, Rajoreya A, Dash SK, Bhagwati G, Chakrabarti S. Gut colonization with carbapenem-resistant enterobacteriaceae adversely impacts the outcome in patients with hematological malignancies: Results of a prospective surveillance study. Mediterr J Hematol Infect Dis. 2018 May 1;10(1):e2018025. doi: 10.4084/MJHID.2018.025.
25. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, Delia M, Ballanti S, Marchesi F, Mancini V, Orciuolo E, Cesaro S, Prezioso L, Fanci R, Nadali G, Chierichini A, Facchini L, Picardi M, Malagola M, Orlando V, Trecarichi EM, Tumbarello M, Aversa F, Rossi G, Pagano L; SEIFEM Group. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018 Sep;97(9):1717-26. doi: 10.1007/s00277-018-3341-6.
26. Micozzi A, Gentile G, Minotti C, Cartoni C, Capria S, Ballarò D, Santilli S, Pacetti E, Grammatico S, Bucaneve G, Foà R. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017 Mar 10;17(1):203. doi: 10.1186/s12879-017-2297-9.
27. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168.
28. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015 Jul;70(7):2133-43. doi: 10.1093/jac/dkv086.
29. Tofas P, Skiada A, Angelopoulou M, Sipsas N, Pavlopoulou I, Tsaousi S, Pagoni M, Kotsopoulou M, Perlorentzou S, Antoniadou A, Pirounaki M, Skoutelis A, Daikos GL. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. Int J Antimicrob Agents. 2016 Apr;47(4):335-9. doi: 10.1016/j.ijantimicag.2016.01.011.
30. Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, Marini V, Arena A, Molin A, Martelli A, Gratarola A, Viscoli C, Pelosi P, Mattioli F. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox? Virulence. 2017 Jan 2;8(1):66-73. doi: 10.1080/21505594.2016.1213476.